Related Experiment Video
Updated: Dec 14, 2025
An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants
Published on: May 22, 2020
Advances in understanding of Rett syndrome and MECP2 duplication syndrome: prospects for future therapies
Alexander J Sandweiss1, Vicky L Brandt2, Huda Y Zoghbi3
1Department of Pediatrics, Section of Neurology and Developmental Neurosciences, Baylor College of Medicine, Houston, TX, USA; Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, Houston, TX, USA.
Abstract:
The X-linked gene encoding MECP2 is involved in two severe and complex neurodevelopmental disorders. Loss of function of the MeCP2 protein underlies Rett syndrome, whereas duplications of the MECP2 locus cause MECP2 duplication syndrome. Research on the mechanisms by which MeCP2 exerts effects on gene expression in neurons, studies of animal models bearing different disease-causing mutations, and more in-depth observations of clinical presentations have clarified some issues even as they have raised further questions. Yet there is enough evidence so far to suggest possible approaches to therapy for these two diseases that could go beyond attempting to address specific signs and symptoms (of which there are many) and instead target the pathophysiology underlying MECP2 disorders. Further work could bring antisense oligonucleotides, deep brain stimulation, and gene therapy into the clinic within the next decade or so.
Insights
Methyl-CpG binding protein 2 (MECP2) gene mutations cause Rett syndrome and MECP2 duplication syndrome. Research suggests targeted therapies, including gene therapy, may treat these neurodevelopmental disorders.
Area of Science:
- Neuroscience
- Genetics
- Developmental Biology
Background:
- The MECP2 gene on the X chromosome is crucial for neurodevelopment.
- Mutations in MECP2 cause two distinct severe neurodevelopmental disorders: Rett syndrome (loss of function) and MECP2 duplication syndrome (duplications).
Purpose of the Study:
- To review current research on MECP2 disorders.
- To explore potential therapeutic strategies targeting the underlying pathophysiology.
Main Methods:
- Review of existing literature on MECP2 gene function, disease mechanisms, animal models, and clinical presentations.
- Analysis of research findings to identify commonalities and differences between Rett syndrome and MECP2 duplication syndrome.
Main Results:
- Research has elucidated MECP2's role in gene expression regulation in neurons.
- Studies in animal models and clinical observations have provided insights into disease mechanisms.
- Despite complexities, evidence suggests potential for pathophysiology-targeted therapies.
Conclusions:
- Existing research supports the development of novel therapeutic approaches for MECP2 disorders.
- Potential therapies include antisense oligonucleotides, deep brain stimulation, and gene therapy.
- These advanced treatments could potentially enter clinical practice within the next decade.
Related Concept Videos
01:22iPS Cell Differentiation
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...